INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Innoviva, Inc.

2000 Sierra Point Parkway
Suite 500
Brisbane, CA 94005
United States
650-238-9600
http://www.inva.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoffrey HulmeInterim Principal Exec. Officer419.64kN/A1967
Ms. Marianne Zhen CPAChief Accounting Officer673.29kN/A1969
Mr. Jeffrey A. Hagenah Ph.D.Chief Patent Counsel and VPN/AN/AN/A
Dr. Kevin KwokHead of Talent Acquisition & StrategyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.

Corporate Governance

Innoviva, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.